Addex Therapeutics Ltd. - נכסים נקיים למניה בודדת ADXN

The book value per share trend for Addex Therapeutics (ADXN) reflects current capital dynamics, where the 2.21 mark indicates the level of net assets. Growth is supported by computer modeling of allosteric modulators to automate compound screening. The strategy relies on licensing agreements and joint developments with mid-sized pharma companies, complementing the creation of safe drugs for epilepsy and Parkinson's disease.

Addex Therapeutics' development of innovative CNS receptor modulation methods requires significant R&D capital expenditures. Analyzing the book value per share under RAS, an investor sees the remaining net assets after deducting all liabilities, allocated per single security. The stability of this metric confirms the preservation of the company's internal capital and the absence of critical write-downs, signaling the business's financial resilience.